Skip to main content
Top
Published in: Breast Cancer Research 2/2005

01-06-2005 | Poster Presentation

A model of the BRCA1/BRCA2 network

Authors: MA Pujana, J-DJ Han, LM Starita, M Tewari, JS Ahn, V Assmann, WM ElShamy, J-F Rual, R Gelman, K Gunsalus, R Greenberg, B Bohian, N Bertin, N Ayivi-Guedehoussou, KL Nathanson, BL Weber, DE Hill, DM Livingston, JD Parvin, M Vidal

Published in: Breast Cancer Research | Special Issue 2/2005

Login to get access

Excerpt

Many genes/proteins have been involved in cellular transformation. However, a systems-level understanding of this pathological process is still absent. To address this question we developed a strategy to generate preliminary models of the networks around known cancer gene products. By examining functional genomic information as gene expression profiles, disease-associated genetic networks and systems-level integrated networks, we defined a 'breast cancer gene module' with predicted novel functional relationships to known breast cancer tumor suppressors. Genes within this module encoded for novel functional relationships with BRCA1 and BRCA2. Among the novel components identified we functionally characterized the hyaluronan-mediated motility receptor (HMMR, human Rhamm), which defines a BRCA1/BRCA2 protein network involved in the control of centrosome number and chromosome segregation. Biochemical data reveal that BRCA1/BRCA2 and HMMR form complexes, that HMMR is ubiquitinated by BRCA1/BARD1, and that BRCA1 and HMMR together regulate centrosome duplication in tissue culture cell lines derived from breast tissue. Our results indicate that similar strategies could help to build and complete other cancer-related cellular networks, and thus to understand how they are affected and/or contribute to cellular transformation. …
Metadata
Title
A model of the BRCA1/BRCA2 network
Authors
MA Pujana
J-DJ Han
LM Starita
M Tewari
JS Ahn
V Assmann
WM ElShamy
J-F Rual
R Gelman
K Gunsalus
R Greenberg
B Bohian
N Bertin
N Ayivi-Guedehoussou
KL Nathanson
BL Weber
DE Hill
DM Livingston
JD Parvin
M Vidal
Publication date
01-06-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1195

Other articles of this Special Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine